Home Depot Inc vs Johnson & Johnson — how do they compare? Home Depot Inc trades at $332.9 (market cap $332.08B), while Johnson & Johnson trades at $249.65 (market cap $598.96B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Home Depot Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| HD | JNJ | |
|---|---|---|
Market Cap | $332.08B | $598.96B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $267.24 |
52-Week Low | $297.51 | $164.36 |
Enterprise Value | $393.64B | $631.90B |
Dividend Yield | 2.8% | 2.15% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $330.95, down 2.34% on the day, approaching its 52-week low amid broader market weakness in home improvement stocks. The company reported mixed quarterly earnings with a Q3 2025 miss but subsequent beats, while maintaining solid profitability with 8.41% net margins and strong ROE of 128.38%. Technical indicators show a bearish trend with key support at $321, while analysts maintain a predominantly bullish outlook with a $370.59 consensus price target representing 12% upside potential.
The outlook balances near-term headwinds from weakening big-ticket demand and rising mortgage rates against long-term strengths in Pro segment growth and housing market tailwinds. Investment opportunities include the stock's discount to analyst targets and resilient business model, while risks include margin pressure from investments, competitive threats, and sensitivity to housing market cycles.
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Trailing returns across standard periods
Latest headlines on both assets
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →